Clinical Trial

Glucose Metabolism in Cystic Fibrosis Related Diabetes (CFRD)

Enrolling by Invitation
View on ClinicalTrials.gov →
Summary
The study aims to test whether use of CFTR modulators (ETI) improves fasting and post prandial glycemia by enhancing disposition index (DI) in individuals with CFRD with CFTR +ve mutation (at least one copy of F508del) on CFTR modulator (ETI) therapy (CFRDF508del+ETI). CFRD with a mutation that is not eligible for modulator therapy (CFRD-ETI) will be the control group.
Protocol Amendment History 4 changes
critical Trial status changed: Recruiting → Enrolling by Invitation 2026-08-04
critical Recruitment opened 2026-06-02
notable Primary completion moved earlier: 2028-06-01 -> 2028-05-01 2026-06-02
minor Completion moved earlier: 2028-12-01 -> 2028-05-28 2026-06-02
Trial Details
NCT Number NCT07102043
Lead Sponsor University of Alabama at Birmingham
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions Cystic Fibrosis Related Diabetes
Enrollment 30 participants
Start Date 2026-05-28
Primary Completion 2028-05-01 (estimated)
Study Completion 2028-05-28 (estimated)
Updated on ClinicalTrials.gov 2026-08-03